Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 45Breast Neoplasms 39Triple Negative Breast Neoplasms 19Prostatic Neoplasms 17Neoplasms 13Fallopian Tube Neoplasms 13Endometrial Neoplasms 12Recurrence 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Lung Neoplasms 6Carcinoma, Ovarian Epithelial 6Glioma 5Glioblastoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Sarcoma 4Carcinoma, Squamous Cell 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Stomach Neoplasms 3Solid Tumor 3Melanoma 3Head and Neck Neoplasms 3Fanconi Anemia, Complementation Group D1 3Uveal Melanoma 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

olaparib 1decitabine and cedazuridine drug combination 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × BRCA1 Mutation × olaparib × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡